Uterotonic Agent Market Size, Industry Share, Growth, 2030

Industry Prospective:

The global uterotonic agent market size was worth around USD 81.47 million in 2022 and is predicted to grow to around USD 156.74 million by 2030 with a compound annual growth rate (CAGR) of roughly 8.52% between 2023 and 2030. The report analyzes the global uterotonic agent market drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the uterotonic agent industry.

Request Free Sample

Uterotonic Agent Market: Overview

A uterotonic agent which is also known as an oxytocic agent is a type of substance or medication that is used to stimulate uterine contractions. These agents help induce labor or manage postpartum hemorrhage which refers to excessive bleeding after childbirth. They are prescribed by doctors for the treatment of certain types of gynecological conditions. The primary uterotonic agent is oxytocin. It is a hormone produced naturally by the body and stimulates the uterus muscles, causing them to contract. It is extremely important medicine during childbirth since it is known to promote labor contractions thus facilitating the delivery of the child.

Key Insights:

• As per the analysis shared by our research analyst, the global uterotonic agent market is estimated to grow annually at a CAGR of around 8.52% over the forecast period (2023-2030)
• In terms of revenue, the global uterotonic agent market size was valued at around USD 81.47 million in 2022 and is projected to reach USD 156.74 million, by 2030.
• The uterotonic agent market is projected to grow at a significant rate due to the growing rate of childbirth
• Based on route of administration segmentation, parenteral was predicted to show maximum market share in the year 2022
• Based on distribution channel segmentation, hospital pharmacy was the leading channel in 2022
• On the basis of region, North America was the leading revenue generator in 2022

Request Free Sample

Uterotonic Agent Market: Growth Drivers

Increasing childbirth rate to propel market growth

The global uterotonic agent market is projected to grow owing to the increasing rate of childbirth across the globe. The medication plays an important role during the delivery of a child since it stimulates uterine contractions. They are used to accelerate or initiate labor when it does not occur or progresses naturally. By stimulating uterine muscles, they dilate the cervix thus assisting in childbirth. One of the significant or commonly observed risks that may occur during delivery is postpartum hemorrhage which leads to excessive bleeding after childbirth. In such cases, uterotonic agents are administered immediately after delivery to prevent or reduce the risk of postpartum hemorrhage.

Uterotonic Agent Market: Restraints

Associated side effects to restrict market expansion

The global uterotonic agent industry may fail to reach its true potential owing to the growing concerns over the associated side effects of uterotonic agents. Like any other medication, these agents may also induce certain unwanted symptoms when administered. Some of the negative impacts include hyperstimulation, hypertonic contractions, uterine rupture, or other reactions. This has led to certain segments of the medical community raising doubts over the efficiency of the medication, especially in terms of dosage and accurate use.

Uterotonic Agent Market: Opportunities

Growing importance of maternal health to provide growth opportunities

The global uterotonic agent market is expected to come across several growth opportunities owing to the increasing importance of maternal health. This can be seen in rigorous research and development activities conducted across the globe to reduce maternal mortality rates. Certain countries lack adequate infrastructure to ensure that new mothers have access to quality care. However, regional leaders with the aid of healthcare organizations are actively working toward improving the architecture.

Uterotonic Agent Market: Challenges

Access and distribution challenges to limit market expansion

In several parts of the world, women do not have access to medicines that are needed for female-oriented issues including hygiene products as maternal care items. The disruption in the supply chain induced due to changing political scenarios and social or economic disruption has further worsened the situation. The lack of access or challenges faced during the distribution of the products such as uterotonic agents could limit the global market expansion during the forecast period.

Uterotonic Agent Market: Segmentation

The global uterotonic agent market is segmented based on route of administration, drug, distribution channel, indication, and region.

Based on route of administration, the global market segments are parenteral, oral, and others. In 2022, the uterotonic agent industry witnessed the highest growth in the parenteral route of administration. The medication or the agent is administered through infusions or injections directly into the body. Such a method of medication administration is highly effective since it allows for reliable and rapid absorption of the medicine into the bloodstream. This means the result is achieved faster. The most common methods of parenteral routes of administration are intravenous (IV) administration and intermuscular (IM) injection. In the former method, the medication is administered as a bolus injection or as a continuous infusion. In the latter method, the medication is administered into the thigh muscles of the upper outer quadrant of the buttock. India’s current birth rate is 16.949 births per 1000 people as per Macrotrends.

Based on drug, the uterotonic agent industry segments are mifepristone, carboprost, dinoprostone, methylergonovine, and others.

Based on distribution channel, the global market segments are online pharmacy, hospital pharmacy, and retail pharmacy. During the forecast period, the hospital pharmacy segment is likely to continue its dominance since uterotonic agents are typically used in a hospital or clinical setting, such as during labor or childbirth. Hence they are, in most cases, distributed through hospital pharmacies. These units are created to cater to the needs of the healthcare professional and hence are always equipped with medicines or any other object the hospital may need. The items are available within the hospital premises. They play an irreplaceable role in procuring, storing, and dispensing uterotonic agents to healthcare professionals that are involved in the crucial task of obstetric care. In 2022, more than 8000 million were born across the globe.

Based on indication, the global market segments are abortion, postpartum hemorrhage, labor, and others.

Recent Developments:

• In February 2022, a report was published on IntechOpen which spoke of the recent advancements in the use of uterotonic agents to prevent postpartum hemorrhage. The report spoke to Carbetocin which is an analog of Oxytocin that has been added to the list of uterotonic agents that can be used to manage the condition. The study also concluded that the optimal method of using the medicine is still under research and further studies would be needed
• In October 2022, March of Dimes, a US-based non-profit organization that works for improving the health of mothers and children, released its latest report called The Nowhere to Go: Maternity Care Deserts Across the U.S. The report clearly stated that maternity care in the country is reducing at a rapid rate and impacting the lives of nearly 7 million women of childbearing age along with over 500,000 babies.

Uterotonic Agent Market: Report Scope

Uterotonic Agent Market: Regional Analysis

North America to generate the highest growth rate

The global uterotonic agent market is expected to witness the highest growth in North America with the regions of Canada and the US leading with the largest part of the regional market share. These countries are home to a robust medical infrastructure where almost the entire population is covered by several types of government healthcare schemes. They have better access to primary medical care which allows them to ensure maternal care as well. In addition to this, the increasing initiatives undertaken by non-profit organizations and local healthcare bodies to upgrade the care systems and reduce maternal morbidity rates could lead to higher growth during the forecast period. However, it should be noted that the approval from the US Food and Drugs Administration process for pregnancy and childbirth-related medicines is extremely complex which is further complicated by local laws surrounding the use of such medicines.

Uterotonic Agent Market: Competitive Analysis

The global uterotonic agent market is led by players like:

• Pfizer Inc.
• Novartis International AG
• Merck & Co. Inc.
• Ferring Pharmaceuticals
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Fresenius Kabi AG
• Bayer AG
• Sanofi S.A.
• Janssen Pharmaceuticals
• Inc. (a subsidiary of Johnson & Johnson)
• Bristol-Myers Squibb Company
• Hikma Pharmaceuticals PLC
• Aspen Pharmacare Holdings Limited
• Sun Pharmaceutical Industries Ltd.
• Lupin Limited
• Torrent Pharmaceuticals Ltd.
• Aurobindo Pharma Limited
• Sandoz International GmbH (a subsidiary of Novartis)
• Zydus Cadila
• Cipla Limited
• Glenmark Pharmaceuticals Ltd.
• Abbott Laboratories. Dr. Reddy's Laboratories Ltd.
• Hologic Inc.
• Lactalis International.

The global uterotonic agent market is segmented as follows:

By Route of Administration

• Parenteral
• Oral
• Others

By Drug

• Mifepristone
• Carboprost
• Dinoprostone
• Methylergonovine
• Others

By Distribution Channel

• Online Pharmacy
• Hospital Pharmacy
• Retail Pharmacy

By Indication

• Abortion
• Postpartum Hemorrhage
• Labor
• Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of The Middle East & Africa